Friday - May 8, 2026
Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency
May 07, 2026
NEW YORK, May 7 [Category: BizFinancial Services] -- Blackstone, an investment firm, posted the following news release:

* * *

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency

People with exocrine pancreatic insufficiency currently face highly disruptive pill burden - ANG003 expected to only require one tablet per meal

NEW YOR . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products